Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Infection and Immunity
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About IAI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Microbial Immunity and Vaccines

Human Antibody Response to Helicobacter pylori Lipopolysaccharide: Presence of an Immunodominant Epitope in the Polysaccharide Chain of Lipopolysaccharide

Shin-ichi Yokota, Ken-ichi Amano, Shunji Hayashi, Toru Kubota, Nobuhiro Fujii, Takashi Yokochi
Shin-ichi Yokota
Sumitomo Pharmaceuticals Research Center, Konohana-ku, Osaka 554,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken-ichi Amano
Central Research Laboratory, Akita University School of Medicine, Akita 010,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunji Hayashi
Department of Microbiology, Sapporo Medical University, Sapporo 060, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toru Kubota
Department of Microbiology, Sapporo Medical University, Sapporo 060, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobuhiro Fujii
Department of Microbiology, Sapporo Medical University, Sapporo 060, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Yokochi
Department of Microbiology, Aichi Medical School, Nagakute, Aichi 480-11, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/IAI.66.6.3006-3011.1998
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We have examined the antibody response to Helicobacter pylori lipopolysaccharides (LPS) in humans. We used sera from patients with gastroduodenal diseases and healthy adults infected or not infected with H. pylori. Data from the experiments for antibody binding to LPS suggested that the polysaccharide chains from many H. pylori strains showed high immunogenicity in humans. Sera from most (above 70%) H. pylori-infected individuals contained immunoglobulin G (IgG) antibodies against the polysaccharide region highly immunogenic H. pylori LPS. The IgG titers of individual serum samples that reacted strongly with highly immunogenic LPS were quite similar (r2 = 0.84 to 0.98). The results suggest wide distribution among H. pylori strains of a highly antigenic epitope in the polysaccharide moieties of their LPS. Also, the similarity in the titers of individual serum samples against highly immunogenic LPS points to the existence of epitopes sharing a common structural motif. However, some strains showed low antigenicity, even those with polysaccharide-carrying LPS. The dominant subclass of IgG that reacted with the highly immunogenic LPS was IgG2, which was preferentially raised against polysaccharide antigens. Recently, a structure that mimics that of the Lewis antigens was identified in the O-polysaccharide fraction of H. pylori LPS; however, no correlation between antigenicity of the polysaccharide chain in humans and the presence of Lewis antigens was found. The IgA and IgM titers against H. pylori LPS seemed to be mostly nonspecific and directed against lipid A. In a few cases, however, sera from individuals infected with H. pylori gave strong IgA and IgM titers against the highly immunogenic polysaccharide. In conclusion, the LPS of many H. pylori strains possess an antigenic epitope in their polysaccharide regions that is immunogenic in humans. However, our results show that the antigenic epitope is unlikely to be immunologically related to structures mimicking Lewis antigens.

Helicobacter pylori is an emerging candidate for the genesis of chronic gastritis and peptic ulcer (12, 14). Furthermore, H. pyloriinfection is thought to be one of the causative factors of gastric cancer (10, 15). Recently, extensive structural and immunological studies of H. pylori lipopolysaccharides (LPS) have been carried out. The O-polysaccharide region of H. pylori LPS has been found to be a major antigenic determinant (13), as are those of other typical bacterial LPS. Interestingly, many H. pylori strains have O-polysaccharide containing epitopes that mimic the structures of Lewis antigens, as shown by chemical (6, 7) and immunological studies (2, 3, 18, 20, 23). The Lewis antigens, which are made up of fucosylated lactosamine structures, are known as tumor antigens on cancer cells, and in normal cells they occur as blood-group antigens and a granulocyte marker antigen (CD15). Hence, the immunological response to the Lewis antigen-containing O-polysaccharides is considered to play a role in the pathogenicity of H. pylorithrough the establishment of an autoimmune response (3). We have been interested in the antigenicity of H. pylori LPS during natural infection in humans. We present data which suggest the existence of an antigenic epitope, immunologically unrelated to the Lewis antigen, in the polysaccharide moiety of the LPS of a wide range of H. pylori strains.

Bacterial strains.Clinical strains of H. pyloriwere isolated from the biopsy specimens of lesions obtained from patients with chronic gastritis, gastric ulcer, duodenal ulcer, and gastric cancer (tumor sites and nontumor sites) in the Sapporo Medical University Hospital (Sapporo, Japan). After three to five laboratory subcultures, H. pylori cells were grown on brain heart infusion agar plates supplemented with 10% (vol/vol) horse blood at 37°C for 5 days under microaerophilic conditions by using the GasPak System without a catalyst (BBL, Cockeysville, Md.). The organisms were collected, washed with phosphate-buffered saline (PBS) three times, and lyophilized.

Human sera.Sera of 25 patients with chronic gastritis, gastric ulcer, duodenal ulcer and gastric cancer and sera of 83 healthy adult volunteers were donated by the Hospitals of Sapporo Medical University and Akita University School of Medicine (Akita, Japan). The status of H. pylori infection was determined by using an enzyme immunoassay kit, Determiner H. pylori Antibody, originally distributed under the name HM-CAP by Enteric Products (Westbury, N.Y.) and purchased from Kyowa Medics (Tokyo, Japan). With this kit, the serum samples of 24 of 25 patients and 21 of 83 healthy adults were found to be positive for H. pylori infection.

IgG response to H. pylori LPS.We examined the human antibody response to LPS isolated from H. pyloristrains by enzyme-linked immunosorbent assay (ELISA). For most ELISA experiments, proteinase K-treated bacterial cells were used as an LPS antigen (2, 24). Briefly, H. pylori cells were suspended in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (11) at a concentration of 2 mg/ml and incubated at 100°C for 10 min. Two hundred microliters of proteinase K (2.5 mg/ml) was added, and the mixture was incubated at 37°C overnight and then at 65°C for 2 h. The resulting antigen was diluted 50-fold with 50 mM sodium carbonate buffer (pH 9.6), and aliquots were dispensed into a MicroTest III flexible assay plate (Becton Dickinson, Oxnard, Calif.). The plate was incubated at 4°C overnight, and after the reaction was blocked with 1% human serum albumin, the plate was used for ELISA (24). For purified LPS preparations used as coated antigens, an LPS preparation which was purified as described previously (1) was dissolved in 50 mM sodium carbonate buffer (pH 9.8) at a concentration of 5 μg/ml and then dispensed onto an assay plate. Human serum was diluted 3,000-fold with PBS containing 0.05% Tween 20 (PBST) and 2% human serum albumin. Horseradish peroxidase-conjugated goat F(ab′)2 anti-human immunoglobulin G (IgG) antibodies (BioSource International, Camarillo, Calif.) and tetramethylbenzidine peroxidase substrate system (Kirkegaard & Perry Laboratories Inc.) were second antibody and substrate, respectively. Absorbance at 450 nm was measured after the termination of the reaction with 1 M phosphoric acid. The results of two ELISAs, with purified LPS and proteinase K-treated cells used as antigens, and immunoblotting analysis (24) were comparable.

We found that H. pylori strains could be classified into three groups on the basis of the level of antigenicity of their LPS in humans (24). One group possessed high-antigenicity-polysaccharide-carrying smooth LPS. The second group had low-antigenicity-polysaccharide-carrying smooth LPS. Most H. pylori-infected individuals did not have an antibody titer against the low-immunogenicity LPS even though the LPS carried the polysaccharide chains detected by SDS-PAGE and silver staining (24; data not shown). The third group was characterized by the presence of rough LPS (e.g., CG10). We examined samples for correlation between the levels of IgG in individual serum samples for each type of LPS (Table 1). The levels of IgG for highly immunogenic H. pylori LPS derived from strains CG7, CG9, GU2, GU10, DU1, and DU2 were strongly (r2 = 0.84 to 0.98) related. These results indicated that the antigenicities of all the highly immunogenic LPS were nearly the same. However, no significant correlation was observed between the titers of IgG for high-immunogenicity LPS, low-immunogenicity LPS (CA2, CA4, and CA6), and rough LPS (CG10). From the above results, we consider that the antigenicity of H. pylori LPS in humans can be expressed by the mean values of the binding activities to LPS in randomly selected serum samples fromH. pylori-infected individuals. The results of ELISA using 10 randomly selected serum samples are shown in Fig.1. LPS of H. pylori clinical isolates showed various antigenicities. Among them, all the rough strains tested so far showed low antigenicity. The phenomenon is attributable to the antigenic epitope located in the polysaccharide chain. Interestingly, low-immunogenicity LPS, even those with the polysaccharide chain, were frequently found in strains derived from gastric cancer patients. In conclusion, there are high- and low-antigenicity-polysaccharide-carrying LPS among smooth strains ofH. pylori.

View this table:
  • View inline
  • View popup
Table 1.

Correlation (r2) of titers of IgG antibody in serum samples tested to LPS fractions from H. pylori strains and S. minnesota Re mutant

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Antigenicity of H. pylori LPS from clinical isolates. Antigenicity is expressed as the mean values of the ELISA reading (A450) for a random selection of 10 serum samples from patients and healthy adults with H. pylori infection. Smooth and rough chemotypes were discriminated by SDS-PAGE and silver staining as described previously (2).

Many H. pylori strains are known to express Lewis antigen structures as a part of the O-polysaccharide chain of LPS (2, 3, 20, 23). Therefore, we determined if the antigenicity of the LPS correlated with the presence of Lewis antigens. The antigenicity of LPS was determined as described above. The presence of structures mimicking the Lewis antigens in LPS was determined by immunoblotting analysis with monoclonal antibody specific for each Lewis antigen described previously (2). Strains with neither high nor low immunogenicity showed a preference for any Lewis antigens (Table2). The results indicate that the antigenicity of H. pylori LPS is unrelated to the presence of the Lewis antigens.

View this table:
  • View inline
  • View popup
Table 2.

Comparison of the Lewis antigen distribution in the LPS fraction from 59 smooth strains of H. pylori and the antigenicity of these LPS fractions in humans

IgG subclass of anti-H. pylori LPS antibody.The subclass of IgG specific for high-immunogenicity H. pyloriLPS was determined by ELISA using human IgG subclass-specific murine monoclonal antibodies. An LPS preparation derived from H. pylori GU2 was coated onto a microplate as described above. Human serum was diluted 1:1,000 (for IgG1 and IgG2) or 1:300 (for IgG3 and IgG4) with PBST, applied to an LPS-coated plate, and incubated at 37°C for 2 h. After the plate was washed with PBST, murine anti-human IgG subclass-specific monoclonal antibodies (500-fold dilution) were dispensed onto the plate and incubated at 37°C for 2 h. Anti-human IgG1 (Fc) (clone 8c/6-39, murine IgG2a), anti-human IgG2 (Fab) (clone HP6014, murine IgG1), anti-human IgG3 [F(ab)2] (clone HP6050, murine IgG1), and anti-human IgG4 (pFc) (clone HP6023, murine IgG3) were purchased from The Binding Site Ltd. (Birmingham, United Kingdom). After the plate was washed, horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) antibodies (human immunoglobulin adsorbed) (Biosource International) was dispensed onto the plate and incubated at 37°C for 2 h. Antibody binding was developed with the TMB peroxidase substrate system as described above. As shown in Fig. 2, IgG2 was found to be dominant type in almost all the sera. The results suggested that the titer of IgG to high-immunogenicity H. pylori LPS ofH. pylori-infected individuals was restricted to the IgG2 subclass. This response is normally attributed to antibodies against bacterial polysaccharide antigens in a T-cell-independent manner (9, 16, 19, 25). Steer et al. (21) determined the IgG subclass response to H. pylori using acid extract as the antigen. IgG1 and IgG4 were significantly present in gastroduodenal patients, and an IgG2 titer was found in 63% of the patients. The value for the IgG2-positive patients was very similar to that of anti-H. pylori LPS IgG2-positive individuals with H. pylori infection described in this study. As mentioned above, manyH. pylori LPS share epitopes that mimic the structures of the host carbohydrate antigens, namely, the Lewis antigens. Similarly,Campylobacter jejuni LPS have structures that mimic gangliosides such as GM1 and GQ1b (4, 5, 17, 27, 28). The host carbohydrate antigen-bearing LPS elicit the pathogenic autoantibodies during C. jejuni infection and may result in neuronal diseases such as Guillain-Barré syndrome and Miller-Fisher syndrome. Interestingly, the anti-C. jejuniLPS antibodies which react to host gangliosides in the patients are restricted predominantly to IgG1 and IgG3 classes (22, 26). These are the subclasses normally found as antibodies against protein antigens in T-cell-dependent responses. In the present study, the antibodies that responded to H. pylori LPS were restricted to predominantly the IgG2 class in both gastroduodenal patients and healthy adults. This finding clearly represents a point of distinction between gastroduodenal diseases caused by H. pyloriinfection and neuronal diseases subsequent to C. jejuniinfection.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Determination of the IgG subclass of highly immunogenicH. pylori LPS-specific antibodies in human sera. LPS derived from strain GU2 was coated onto a microplate. Human serum (1,000-fold dilution) was applied to the plate. Subsequently, human IgG subclass-specific murine monoclonal antibodies, peroxidase-conjugated goat anti-mouse IgG antibodies, and TMB substrate solution were applied. Binding activity was expressed as absorbance at 450 nm.

IgM and serum IgA responses.We examined the titers of IgM (Fig. 3) and IgA (Fig.4) to H. pylori LPS in sera by ELISA. ELISA was carried out as described above, except that 300-fold diluted human serum and horseradish peroxidase-conjugated human IgM- or IgA-specific antibodies (BioSource International) were used as first and second antibodies, respectively. We used Salmonella minnesota Re mutant LPS (Sigma, St. Louis, Mo.) as a control to determine the level of nonspecific anti-LPS antibodies. The Re mutant has a severe defect in its LPS structure; namely, its LPS consists of lipid A and possesses only one 3-deoxyoctulosonic acid residue. Most individual serum samples contained nonspecific anti-LPS antibodies that were mainly IgM and IgA. We succeeded in showing that nonspecific binding to LPS could be discerned by comparison of the antibody titer to that of the Re-type LPS. The IgM and IgA titers of sera to low-immunogenicity LPS (e.g., CA6) and rough LPS (e.g., CG10) could be attributed to such nonspecific anti-LPS antibodies, as the titers were closely related to the antibody titer of Salmonella Re-type LPS (Fig. 3 and 4). However, only 3 of 25 patients and 1 of 21 healthy adults with H. pylori infection were positive for H. pylori LPS-specific IgA, and one healthy adult with H. pylori infection was positive for H. pylori-specific IgM. The specificity of the IgA and IgM titer to H. pyloriLPS was similar to that of IgG; namely, the IgA and IgM antibodies that bound to high-immunogenicity LPS did not bind to low-immunogenicity LPS (data not shown). The results indicated that antibody response to the antigenic epitope was not restricted to IgG but that IgA and IgM were detected in some serum samples. An IgM titer to the antigenic epitope of the high-immunogenicity H. pylori LPS was detected in oneH. pylori-infected healthy adult, and IgA titers were detected in a few gastroduodenal patients. As the IgM-positive individual had a low titer of IgG to the antigenic epitope, the individual was most probably in an acute phase of infection. A high IgA titer was more frequently found in the patients with gastric diseases. The IgA response seemed to be related to the mucosal immunity in the gastroduodenal disease state during chronic H. pyloriinfection.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Relationship of the IgM titer of human sera to H. pylori LPS derived from a strain with high antigenicity (GU2), a strain with low antigenicity (CA6), and a rough strain (CG10) andS. minnesota rough (Re-type) LPS as determined by ELISA. Human sera were diluted 1:300. The human sera were donated by patients with gastroduodenal disease (•), healthy adults with H. pylori infection (▪), and healthy adults without H. pylori infection (▴).

Fig. 4.
  • Open in new tab
  • Download powerpoint
Fig. 4.

Relationship of the titer of IgA in human sera toH. pylori LPS derived from a strain with high antigenicity (GU2), a strain with low antigenicity (CA6), and a rough strain (CG10) and S. minnesota rough (Re-type) LPS as determined by ELISA. Human serum was diluted 1:300. The human sera were donated by patients with gastroduodenal disease (•), healthy adults with H. pylori infection (▪), and healthy adults without H. pylori infection (▴).

Significant findings of this study.Recently, H. pylori LPS was shown to have Lewis antigens in the O-polysaccharide chain of its LPS (3, 6-8, 18, 20, 23). The presence of such epitopes mimicking host antigens was suggested to elicit an autoimmune response (3). In this study, we carefully examined the antibody response to H. pylori LPS inH. pylori-infected gastric disease patients and in infected and uninfected healthy adults. We proposed that there was an epitope antigenic to humans on the polysaccharide chain of H. pyloriLPS. The antigenic epitope was distributed among many H. pylori strains but not all strains. Strains having the antigenic epitope showed high immunogenicity. In contrast, strains lacking the epitope in the polysaccharide chains and rough strains, namely, strains lacking the polysaccharide chain, showed low antigenicity. We found that few human serum samples contained high titers of antibody specific for the low-immunogenicity LPS but not for the high-immunogenicity ones. The titers of IgG to high-immunogenicity LPS were quite similar to one another. The evidence suggests little variation in the nature of the antigen in the highly immunogenic polysaccharide of LPS amongH. pylori strains. The antigenic epitope would appear to be a defined structure in the polysaccharide chain of LPS. However, the structure of the antigenic epitope remains to be defined.

Appelmelk et al. (3) pointed out the presence of an IgG titer to Lewis X antigen (Lex)-bearing LPS in the sera ofH. pylori-infected patients. However, they used only three strains, two Lex-positive strains and one Lex-negative strain. We have shown that antigenicity was not related to the existence of any Lewis antigens in about 60 smooth strains of H. pylori. Therefore, we suggest that the mimicry of the Lewis antigen by H. pylori is probably not important for antigenicity in humans. This result is also supported by the observation that an anti-Lewis antigen antibody titer can be detected in human sera independently of H. pylori LPS (2). Indeed, the anti-Lex antibodies were produced by immunization of mice and rabbits with H. pylori cells (3). There may be differences in the immune responses between active immunization in animals and natural infection in humans. On the other hand, we found that the antigenic epitope was related to the clinical sources of the strains. The epitope was frequently lacking in H. pylori strains derived from tumors of gastric cancer patients, an interesting observation described in detail elsewhere (24). However, sera of cancer patients did not contain significantly higher antibody titers to the low immunogenic LPS than those to the high immunogenic LPS. Many of the serum samples from gastric cancer patients contained antibody titers to the antigenic epitope (data not shown).

In conclusion, the epitopes that mimic the structures of the Lewis antigens in H. pylori LPS do not seem to be those that predominate during natural infections in humans. We conclude that the Lewis antigen-related epitopes do not play a major role in the pathogenicity of H. pylori with regard to gastroduodenal diseases, such as chronic gastritis, peptic ulcer, and gastric cancer.

ACKNOWLEDGMENTS

We are grateful to T. Ishioka and O. Urayama of Akita University School of Medicine for providing sera from healthy individuals and patients suffering from gastric diseases.

FOOTNOTES

    • Received 3 September 1997.
    • Returned for modification 22 January 1998.
    • Accepted 3 April 1998.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Amano K.,
    2. Fujita M.,
    3. Suto T.
    Chemical properties of lipopolysaccharides from spotted fever group rickettsiae and their common antigenicity with lipopolysaccharides from Proteus species. Infect. Immun. 61 1993 4350 4355
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Amano K.,
    2. Hayashi S.,
    3. Kubota T.,
    4. Fujii N.,
    5. Yokota S.
    Reactivities of Lewis antigen monoclonal antibodies to the lipopolysaccharides of Helicobacter pylori strains isolated from patients with gastroduodenal diseases in Japan. Clin. Diagn. Lab. Immunol. 4 1997 540 544
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Appelmelk B. J.,
    2. Simoons-Smit I.,
    3. Negrini R.,
    4. Moran A. P.,
    5. Aspinall G. O.,
    6. Forte J. G.,
    7. de Vries T.,
    8. Quan H.,
    9. Verboom T.,
    10. Maaskant J. J.,
    11. Ghiara P.,
    12. Kuipers E. J.,
    13. Bloemena E.,
    14. Tadema T. M.,
    15. Townsend R. R.,
    16. Tyagarajan K.,
    17. Crothers J. M. Jr.,
    18. Monterio M. A.,
    19. Savio A.,
    20. de Graaff J.
    Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect. Immun. 64 1996 2031 2040
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Aspinall G. O.,
    2. Fujimoto S.,
    3. McDonald A. G.,
    4. Pang H.,
    5. Kurjanczyk L. A.,
    6. Penner J. L.
    Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barré syndrome mimic human gangliosides in structure. Infect. Immun. 62 1994 2122 2125
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Aspinall G. O.,
    2. McDonald A. G.,
    3. Raju T. S.,
    4. Pang H.,
    5. Mills S. D.,
    6. Kurjanczyk L. A.,
    7. Penner J. L.
    Serological diversity and chemical structures of Campylobacter jejuni low-molecular-weight lipopolysaccharides. J. Bacteriol. 174 1992 1324 1332
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Aspinall G. O.,
    2. Monteiro M. A.
    Lipopolysaccharide of the Helicobacter pylori strains P466 and MO19: structures of the O antigen and core oligosaccharide regions. Biochemistry 35 1996 2498 2504
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Aspinall G. O.,
    2. Monteiro M. A.,
    3. Pang H.,
    4. Walsh E. J.,
    5. Moran A. P.
    Lipopolysaccharide of the Helicobacter pylori type strain NCTC 11637 (ATCC 43504): structure of the O antigen chain and core oligosaccharide regions. Biochemistry 35 1996 2489 2497
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Aspinall G. O.,
    2. Monteiro M. A.,
    3. Pang H.,
    4. Walsh E. J.,
    5. Moran A. P.
    O antigen chains in the lipopolysaccharide of Helicobacter pylori NCTC 11637. Carbohydr. Lett. 1 1994 151 156
    OpenUrl
  9. 9.↵
    1. Barrett D. J.,
    2. Ayoub E. M.
    IgG2 subclass restriction of antibody to pneumococcal polysaccharide. Clin. Exp. Immunol. 63 1986 127 134
    OpenUrlPubMedWeb of Science
  10. 10.↵
    The Eurogast Study Group An international association between Helicobacter pylori infection and gastric cancer. Lancet 341 1993 1359 1362
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Laemmli U. K.
    Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 1970 680 685
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Marshall B. J.
    Unidentified curved bacilli on gastric epithelium in chronic gastritis. Lancet i 1983 1273 1313
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Mills S. D.,
    2. Kurjanczyk L. A.,
    3. Penner J. L.
    Antigenicity of Helicobacter pylori lipopolysaccharides. J. Clin. Microbiol. 30 1992 3175 3180
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Diseases Helicobacter pylori in peptic ulcer diseases. JAMA 272 1994 65 69
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Parsonnet J.,
    2. Friedmann G. D.,
    3. Vandersteen D. P.,
    4. Orentreich N.,
    5. Sibley R. K.
    Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325 1991 1127 1131
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Risen W. F.,
    2. Skvaril F.,
    3. Braun D. G.
    Natural infection of man with group A streptococci. Levels, restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies. Scand. J. Immunol. 5 1976 383 390
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Salloway S.,
    2. Mermel L. A.,
    3. Seamans M.,
    4. Aspinall G. O.,
    5. Nam Shin J. E.,
    6. Kurjanczyk L. A.,
    7. Penner J. L.
    Miller-Fisher syndrome associated with Campylobacter jejuni bearing lipopolysaccharide molecules that mimic human ganglioside GD3. Infect. Immun. 64 1996 2945 2949
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Sherburne R.,
    2. Taylor D. E.
    Helicobacter pylori expresses a complex surface carbohydrate, Lewis X. Infect. Immun. 63 1995 4564 4568
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Siber G. R.,
    2. Schur P. H.,
    3. Aisenberg A. C.,
    4. Weitzman S. A.,
    5. Schiffman G.
    Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N. Engl. J. Med. 303 1980 178 182
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Simoons-Smit I. N.,
    2. Appelmelk B. J.,
    3. Verboom T.,
    4. Negrini R.,
    5. Penner J. L.,
    6. Aspinall G. O.,
    7. Moran A. P.,
    8. Fei S. H.,
    9. Bi-Shan S.,
    10. Rudnica W.,
    11. Savio A.,
    12. de Graaff J.
    Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide. J. Clin. Microbiol. 34 1996 2196 2200
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Steer H. W.,
    2. Hawtin P. R.,
    3. Newell D. G.
    An ELISA technique for the serodiagnosis of Campylobacter pyloridis infection in patients with gastric and benign duodenal ulceration. Serodiagn. Immunother. 1 1987 253 259
    OpenUrl
  22. 22.↵
    1. Willison H. J.,
    2. Veitch J.
    Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol. 50 1994 159 165
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Wirth H.-P.,
    2. Yang M.,
    3. Karita M.,
    4. Blaser M. J.
    Expression of the human cell surface glycoconjugates Lewis X and Lewis Y by Helicobacter pylori isolates is related to cagA status. Infect. Immun. 64 1996 4598 4605
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Yokota S.,
    2. Amano K.,
    3. Hayashi S.,
    4. Fujii N.
    Low antigenicity of the polysaccharide region of Helicobacter pylori lipopolysaccharides derived from tumors of patients with gastric cancer. Infect. Immun. 65 1997 3509 3512
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Yount W. J.,
    2. Dorner M. M.,
    3. Kunkel H. G.,
    4. Kabat E. A.
    Studies on human antibodies. IV. Selective variations in subgroup composition and genetic markers. J. Exp. Med. 127 1968 633 646
    OpenUrlAbstract
  26. 26.↵
    1. Yuki N.,
    2. Ichihashi Y.,
    3. Taki T.
    Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barré syndrome. J. Neuroimmunol. 60 1995 161 164
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Yuki N.,
    2. Taki T.,
    3. Inagaki F.,
    4. Kasama T.,
    5. Takahashi M.,
    6. Saito K.,
    7. Handa S.,
    8. Miyatake T.
    A bacterium lipopolysaccharide that elicits Guillian-Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178 1993 1771 1775
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Yuki N.,
    2. Taki T.,
    3. Takahashi M.,
    4. Saito K.,
    5. Yoshino H.,
    6. Tai T.,
    7. Handa S.,
    8. Miyatake T.
    Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher’s syndrome. Ann. Neurol. 36 1994 791 793
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Human Antibody Response to Helicobacter pylori Lipopolysaccharide: Presence of an Immunodominant Epitope in the Polysaccharide Chain of Lipopolysaccharide
Shin-ichi Yokota, Ken-ichi Amano, Shunji Hayashi, Toru Kubota, Nobuhiro Fujii, Takashi Yokochi
Infection and Immunity Jun 1998, 66 (6) 3006-3011; DOI: 10.1128/IAI.66.6.3006-3011.1998

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Infection and Immunity article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Antibody Response to Helicobacter pylori Lipopolysaccharide: Presence of an Immunodominant Epitope in the Polysaccharide Chain of Lipopolysaccharide
(Your Name) has forwarded a page to you from Infection and Immunity
(Your Name) thought you would be interested in this article in Infection and Immunity.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Human Antibody Response to Helicobacter pylori Lipopolysaccharide: Presence of an Immunodominant Epitope in the Polysaccharide Chain of Lipopolysaccharide
Shin-ichi Yokota, Ken-ichi Amano, Shunji Hayashi, Toru Kubota, Nobuhiro Fujii, Takashi Yokochi
Infection and Immunity Jun 1998, 66 (6) 3006-3011; DOI: 10.1128/IAI.66.6.3006-3011.1998
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibodies, Bacterial
Antigens, Bacterial
Helicobacter Infections
Helicobacter pylori
Immunodominant Epitopes
Lipopolysaccharides

Related Articles

Cited By...

About

  • About IAI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #IAIjournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0019-9567; Online ISSN: 1098-5522